

Online Supplementary Appendix: Changes in median levels of laboratory variables with thalidomide treatment

Variable	Units	Response category	No. of specimen pairs	Median baseline (range)	Median best response (range)	P value
MVD	per HPF	Response	19	21 (7-71)	10 (4-20)	0.004
VEGF	pg/ml	Response	21	66 (9-562)	43 (0-208)	0.024
bFGF	pg/ml	Response	21	0 (0-135)	0 (0-25)	0.46
IL-6	pg/ml	Response	21	3 (0-107)	6 (0-121)	0.48
HGF	pg/ml	Response	20	1161 (315-12872)	846 (267-17072)	0.16
MCT+ cells	per HPF	Response	19	1 (0-8)	8 (1-21)	<0.001
CD57+ cells	per HPF	Response	17	4 (0-31)	3 (1-9)	0.13
MVD	per HPF	Stable disease	20	22 (2-89)	10 (1-130)	0.25
VEGF	pg/ml	Stable disease	19	34 (0-107)	16 (0-106)	0.45
bFGF	pg/ml	Stable disease	19	0 (0-8)	0 (0-10)	0.36
IL-6	pg/ml	Stable disease	19	4 (0-61)	6 (0-96)	0.17
HGF	pg/ml	Stable disease	19	1156 (449-5290)	946 (466-7745)	0.79
MCT+ cells	per HPF	Stable disease	19	1 (0-17)	5 (0-18)	0.014
CD57+ cells	per HPF	Stable disease	19	3 (0-12)	3 (1-15)	0.13
Variable	Units	Response category	No. of specimen pairs	Median baseline or best response (range)	Median at first progression (range)	P value
MVD	per HPF	Progression	27	10 (1-130)	20 (1-113)	0.027
VEGF	pg/ml	Progression	27	29 (0-387)	26 (0-193)	0.55
bFGF	pg/ml	Progression	27	0 (0-8)	0 (0-25)	0.18
IL-6	pg/ml	Progression	26	5 (0-96)	7 (0-113)	0.01
HGF	pg/ml	Progression	27	946 (541-16540)	1152 (436-12650)	0.49
MCT+ cells	per HPF	Progression	27	2 (1-18)	3 (1-21)	0.88
CD57+ cells	per HPF	Progression	27	2 (1-15)	3 (1-29)	0.41

HPF = High power field (x400)

Variables with significant changes ($p < 0.05$) are bolded

